SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS:CELG), if they purchased the Company’s shares between September 12, 2016 and February 27, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Celgene investors should visit us at https://www.claimsfiler.com/cases/view-celgene-corporation-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Celgene and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On October 19, 2017, the Company disclosed that it was discontinuing trials of its long-touted drug GED-0301 and recording a $1.6 billion impairment charge due to the drug’s failure. Then, on February 27, 2018, the Company revealed that the U.S. Food and Drug Administration had issued a refusal-to-file letter rejecting the New Drug Application (“NDA”) for Ozanimod, another of its leading drug candidates, because “the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.”
On this news, the price of Celgene’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
